Home Clinical trials For patients Ovary REGN4018

REGN4018

Study of REGN4018 administered alone or in combination with Cemiplimab in adult patients with recurrent ovarian cancer or other recurrent mucin-16 expressing (MUC16+) cancers

Open
Trial drug
REGN4018, Cemiplimab
Grade
High grade, Low grade
Prior lines
1, 2, 3, 4
Histology
Serous, Endometrioid Clear-cell Mucinous Other (bv. mixed/rare)
Platin
Platinum sensitive
Platinum resistant
Primary platinum refractory
Secondary platinum refractory
Phase
1/2

Treatment

This study consists of two different treatment options: 

  • REGN4018
  • REGN54018 + Cemiplimab

REGN4018 and Cemiplimab will be administered intravenously.

No randomisation will be performed in this trial. You will be allocated to one of both groups depending on the characteristics of your disease.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.